Kureha Of Japan Signs Development Agreement With LG Lifescience Indian Subsidiary
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Japanese chemical company Kureha Feb. 13 signed an agreement with Indian subsidiary of South Korean pharmaceutical company LG Lifescience. According to the agreement, LG Lifescience obtained exclusive rights to develop and market Kureha's proprietary oral absorbent chronic renal failure treatment Kremezin (AST-120) in India. The company plans a market launch in 2012. Currently available for therapeutic use in Japan, Taiwan and Korea, AST-120 is estimated to expand in other Asian countries as well as in the U.S. and Europe. (Click here for more - Japanese language